Annual CFF
$26.14 M
+$20.79 M+388.27%
December 31, 2023
Summary
- As of February 7, 2025, PBLA annual cash flow from financing activities is $26.14 million, with the most recent change of +$20.79 million (+388.27%) on December 31, 2023.
- During the last 3 years, PBLA annual CFF has risen by +$15.70 million (+150.31%).
- PBLA annual CFF is now at all-time high.
Performance
PBLA Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$2.20 M
+$2.20 M+100.00%
September 30, 2024
Summary
- As of February 7, 2025, PBLA quarterly cash flow from financing activities is $2.20 million, with the most recent change of +$2.20 million (+100.00%) on September 30, 2024.
- Over the past year, PBLA quarterly CFF has dropped by -$2.55 million (-53.67%).
- PBLA quarterly CFF is now -83.95% below its all-time high of $13.70 million, reached on March 31, 2023.
Performance
PBLA Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$14.03 M
+$2.22 M+18.79%
September 30, 2024
Summary
- As of February 7, 2025, PBLA TTM cash flow from financing activities is $14.03 million, with the most recent change of +$2.22 million (+18.79%) on September 30, 2024.
- Over the past year, PBLA TTM CFF has dropped by -$12.11 million (-46.33%).
- PBLA TTM CFF is now -47.58% below its all-time high of $26.77 million, reached on June 30, 2023.
Performance
PBLA TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
PBLA Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +388.3% | -53.7% | -46.3% |
| 3 y3 years | +150.3% | -84.0% | -26.4% |
| 5 y5 years | +617.6% | -84.0% | -26.4% |
PBLA Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +388.3% | -84.0% | >+9999.0% | -47.6% | >+9999.0% |
| 5 y | 5-year | at high | +590.9% | -84.0% | +409.4% | -47.6% | >+9999.0% |
| alltime | all time | at high | >+9999.0% | -84.0% | +409.4% | -47.6% | >+9999.0% |
Panbela Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $2.20 M(>+9900.0%) | $14.03 M(+18.8%) |
| Jun 2024 | - | $0.00(-100.0%) | $11.81 M(-39.5%) |
| Mar 2024 | - | $7.08 M(+49.1%) | $19.52 M(-25.3%) |
| Dec 2023 | $26.14 M(+388.3%) | $4.75 M(<-9900.0%) | $26.14 M(-2.2%) |
| Sep 2023 | - | -$19.00 K(-100.2%) | $26.74 M(-0.1%) |
| Jun 2023 | - | $7.71 M(-43.8%) | $26.77 M(+40.4%) |
| Mar 2023 | - | $13.70 M(+156.2%) | $19.06 M(+256.0%) |
| Dec 2022 | $5.35 M(-47.0%) | $5.35 M(>+9900.0%) | $5.35 M(>+9900.0%) |
| Sep 2022 | - | $5000.00(>+9900.0%) | $6000.00(-99.9%) |
| Jun 2022 | - | $0.00(0.0%) | $9.05 M(0.0%) |
| Mar 2022 | - | $0.00(-100.0%) | $9.05 M(-10.3%) |
| Dec 2021 | $10.10 M(-3.3%) | $1000.00(-100.0%) | $10.10 M(+7.6%) |
| Sep 2021 | - | $9.05 M(>+9900.0%) | $9.38 M(-3.2%) |
| Jun 2021 | - | $0.00(-100.0%) | $9.69 M(-15.8%) |
| Mar 2021 | - | $1.04 M(-246.6%) | $11.51 M(+10.2%) |
| Dec 2020 | $10.44 M(+176.0%) | -$711.00 K(-107.6%) | $10.44 M(-5.9%) |
| Sep 2020 | - | $9.36 M(+413.7%) | $11.09 M(+128.7%) |
| Jun 2020 | - | $1.82 M(-7107.7%) | $4.85 M(+61.7%) |
| Mar 2020 | - | -$26.00 K(-57.4%) | $3.00 M(-20.7%) |
| Dec 2019 | $3.78 M(+3.9%) | -$61.00 K(-102.0%) | $3.78 M(-26.9%) |
| Sep 2019 | - | $3.12 M(<-9900.0%) | $5.17 M(+154.6%) |
| Jun 2019 | - | -$28.00 K(-103.7%) | $2.03 M(-27.2%) |
| Mar 2019 | - | $758.00 K(-43.0%) | $2.79 M(-23.4%) |
| Dec 2018 | $3.64 M | $1.33 M(-5022.2%) | $3.64 M(+57.4%) |
| Sep 2018 | - | -$27.00 K(-103.7%) | $2.31 M(-1.2%) |
| Jun 2018 | - | $730.00 K(-54.7%) | $2.34 M(+41.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2018 | - | $1.61 M(>+9900.0%) | $1.65 M(-46.8%) |
| Dec 2017 | $3.11 M(+62.2%) | $0.00(0.0%) | $3.11 M(-1.3%) |
| Sep 2017 | - | $0.00(-100.0%) | $3.15 M(-7.9%) |
| Jun 2017 | - | $40.00 K(-98.7%) | $3.42 M(-31.4%) |
| Mar 2017 | - | $3.07 M(+7200.0%) | $4.98 M(+160.1%) |
| Dec 2016 | $1.92 M(-28.4%) | $42.00 K(-84.4%) | $1.92 M(+2.2%) |
| Sep 2016 | - | $270.00 K(-83.2%) | $1.87 M(-32.3%) |
| Jun 2016 | - | $1.60 M(>+9900.0%) | $2.77 M(+23.4%) |
| Mar 2016 | - | $0.00(0.0%) | $2.24 M(-16.2%) |
| Dec 2015 | $2.67 M(-5.0%) | $0.00(-100.0%) | $2.67 M(-13.1%) |
| Sep 2015 | - | $1.16 M(+7.9%) | $3.08 M(-28.9%) |
| Jun 2015 | - | $1.08 M(+148.4%) | $4.33 M(+33.2%) |
| Mar 2015 | - | $434.00 K(+7.4%) | $3.25 M(+15.5%) |
| Dec 2014 | $2.81 M(<-9900.0%) | $404.00 K(-83.3%) | $2.81 M(+17.0%) |
| Sep 2014 | - | $2.42 M(<-9900.0%) | $2.41 M(<-9900.0%) |
| Jun 2014 | - | -$1900.00(-13.6%) | -$11.40 K(+7.5%) |
| Mar 2014 | - | -$2200.00(-60.7%) | -$10.60 K(-8.6%) |
| Dec 2013 | -$11.60 K(-268.1%) | -$5600.00(+229.4%) | -$11.60 K(+12.6%) |
| Sep 2013 | - | -$1700.00(+54.5%) | -$10.30 K(-59.6%) |
| Jun 2013 | - | -$1100.00(-65.6%) | -$25.50 K(+363.6%) |
| Mar 2013 | - | -$3200.00(-25.6%) | -$5500.00(-179.7%) |
| Dec 2012 | $6900.00(-22.5%) | -$4300.00(-74.6%) | $6900.00(-38.4%) |
| Sep 2012 | - | -$16.90 K(-189.4%) | $11.20 K(-60.1%) |
| Jun 2012 | - | $18.90 K(+105.4%) | $28.10 K(+205.4%) |
| Mar 2012 | - | $9200.00 | $9200.00 |
| Dec 2011 | $8900.00 | - | - |
FAQ
- What is Panbela Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Panbela Therapeutics?
- What is Panbela Therapeutics annual CFF year-on-year change?
- What is Panbela Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Panbela Therapeutics?
- What is Panbela Therapeutics quarterly CFF year-on-year change?
- What is Panbela Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Panbela Therapeutics?
- What is Panbela Therapeutics TTM CFF year-on-year change?
What is Panbela Therapeutics annual cash flow from financing activities?
The current annual CFF of PBLA is $26.14 M
What is the all time high annual CFF for Panbela Therapeutics?
Panbela Therapeutics all-time high annual cash flow from financing activities is $26.14 M
What is Panbela Therapeutics annual CFF year-on-year change?
Over the past year, PBLA annual cash flow from financing activities has changed by +$20.79 M (+388.27%)
What is Panbela Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of PBLA is $2.20 M
What is the all time high quarterly CFF for Panbela Therapeutics?
Panbela Therapeutics all-time high quarterly cash flow from financing activities is $13.70 M
What is Panbela Therapeutics quarterly CFF year-on-year change?
Over the past year, PBLA quarterly cash flow from financing activities has changed by -$2.55 M (-53.67%)
What is Panbela Therapeutics TTM cash flow from financing activities?
The current TTM CFF of PBLA is $14.03 M
What is the all time high TTM CFF for Panbela Therapeutics?
Panbela Therapeutics all-time high TTM cash flow from financing activities is $26.77 M
What is Panbela Therapeutics TTM CFF year-on-year change?
Over the past year, PBLA TTM cash flow from financing activities has changed by -$12.11 M (-46.33%)